Latest Trials Latest NewsFAQ

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Managing Agitated Delirium with Neuroleptics and Anti-Epileptics As a Neuroleptic Sparing Strategy

Phase 2

Recruiting

Conditions: Neuroleptics
Delirium
Epileptics

Interventions: Drug: Valproate
Drug: Haloperidol
Drug: Chlorpromazine
Drug: Placebo

First Posted Date: 2022-06-24

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05431595

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1

Withdrawn

Conditions: Tumors
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer

Interventions: Drug: ZN-c3
Drug: Bevacizumab
Drug: Pembrolizumab

First Posted Date: 2022-06-24

Last Posted Date: 2023-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05431582

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Phase 2

Recruiting

Conditions: T Cells
Colorectal Cancer
Lynch Syndrome

Interventions: Drug: Naproxen
Drug: Aspirin

First Posted Date: 2022-06-09

Last Posted Date: 2024-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05411718

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study Assessing the Effectiveness of Use of Guided Imagery for Treatment of Pain and Symptom Management in Women With Post-mastectomy Pain Syndrome

Not Applicable

Completed

Conditions: Symptom Management
Pain Syndrome
Pain

Interventions: Other: The Intervention Group
Other: The Control Group

First Posted Date: 2022-06-07

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT05408741

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Recruiting

Conditions: Invasive Breast Carcinoma
Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Radiation: Radiation Therapy

First Posted Date: 2022-06-06

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT05406232

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Breast Cancer
Hepatocellular Carcinoma

Interventions: Drug: Piflufolastat F18

First Posted Date: 2022-05-27

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT05394259

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Metastatic Malignancy

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2022-05-27

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05394337

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

PEER Trial: Part 2 Rice Technologies

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Device: Multimodal optical imaging

First Posted Date: 2022-05-12

Last Posted Date: 2024-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 678

Registration Number: NCT05372484

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇲🇿
Mavalane Hospital and Health Center, Maputo, Mozambique
🇲🇿
José Macamo General Hospital and Health Center, Maputo, Mozambique

and more 1 locations

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Phase 2

Recruiting

Conditions: HPV
Oropharyngeal Cancer

Interventions: Drug: Balstilimab

First Posted Date: 2022-05-06

Last Posted Date: 2024-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05363709

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Phase 2

Recruiting

Conditions: Myelodysplastic Syndromes
Myeloproliferative Chronic Myelomonocytic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2022-05-06

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05365035

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy